Skin autofluorescence as an indicator of advanced glycation end-product accumulation in the prognosis of age-related cardiovascular disease: literature review

Cover Page

Cite item

Full Text

Abstract

Advanced glycation end products (AGEs) are represented by heterogeneous molecular structures and their accumulation in organs and tissues reflects the intensity of oxidative stress and glycemia. As a physiological process, aging is associated with AGE accumulation and changing the morphology and functions of the vascular wall. Accelerated AGE accumulation initiates inflammation, contributing to the development of cardiovascular diseases, such as arterial hypertension, coronary heart diseases, and atherosclerosis of peripheral arteries; conditions associated with high cardiovascular risks such as prediabetes, diabetes mellitus type 2, and chronic kidney diseases are also characterized by the accelerated AGEs accumulation. The ability of AGEs to fluorescence underlies noninvasively in blood serum, tissues, and skin using a well-proven technique of autofluorescence, which is little known to domestic specialists. This review presents the possibilities of autofluorescence to reflect arterial wall remodeling, which includes stiffness, vascular endothelial function, atherosclerotic plaque formation, and instability, using modern materials. The review emphasizes the evidence base regarding the ability of this method to predict mortality and cardiovascular events in a large population from low to high risk.

About the authors

Petr A. Lebedev

Samara State Medical University

Email: palebedev@yahoo.com
ORCID iD: 0000-0003-3501-2354
SPIN-code: 8085-3904

MD, Dr. Sci. (Med.), Professor

Russian Federation, Samara

Naila A. Davydova

Samara State Medical University

Author for correspondence.
Email: palebedev@yahoo.com
ORCID iD: 0000-0003-1956-3690
SPIN-code: 7892-1422

graduate student

Russian Federation, Samara

Elena V. Paranina

Samara State Medical University

Email: palebedev@yahoo.com
ORCID iD: 0000-0001-7021-4061
SPIN-code: 9256-8661

MD, Cand. Sci. (Med.), associate professor

Russian Federation, Samara

Maria A. Skuratova

Samara State Medical University

Email: palebedev@yahoo.com
ORCID iD: 0000-0002-0703-2764
SPIN-code: 6774-6215

MD, Cand. Sci. (Med.)

Russian Federation, Samara

References

  1. Salazar J, Navarro C, Ortega Á, et al. Advanced Glycation End Products: New Clinical and Molecular Perspectives. Int J Environ Res Public Health. 2021;18(14):7236. doi: 10.3390/ijerph18147236
  2. Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics. 2013;92:248–259. doi: 10.1016/j.jprot.2013.05.012
  3. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris). 2010;58(3):214–219. doi: 10.1016/j.patbio.2009.09.014
  4. Rowan S, Bejarano E, Taylor A. Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3631–3643. doi: 10.1016/j.bbadis.2018.08.036
  5. Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev. 2020;2020:3818196. doi: 10.1155/2020/3818196
  6. Reddy VP, Aryal P, Darkwah EK. Advanced Glycation End Products in Health and Disease. Microorganisms. 2022;10(9):1848. doi: 10.3390/microorganisms10091848
  7. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370(Pt 3):1097–1109. doi: 10.1042/BJ20021371
  8. Hanssen NM, Wouters K, Huijberts MS, et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J. 2014;35(17):1137–1146. doi: 10.1093/eurheartj/eht402
  9. Maasen K, van Greevenbroek MMJ, Scheijen JLJM, et al. High dietary glycemic load is associated with higher concentrations of urinary advanced glycation endproducts: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study. Am J Clin Nutr. 2019;110(2):358–366. doi: 10.1093/ajcn/nqz119
  10. Budoff MJ, Alpert B, Chirinos JA, et al. Clinical Applications Measuring Arterial Stiffness: An Expert Consensus for the Application of Cardio-Ankle Vascular Index. Am J Hypertens. 2022;35(5):441–453. doi: 10.1093/ajh/hpab178
  11. Laurent S, Boutouyrie P. Arterial Stiffness and Hypertension in the Elderly. Front Cardiovasc Med. 2020;7:544302. doi: 10.3389/fcvm.2020.544302
  12. Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(1):59. doi: 10.1186/s10020-018-0060-3
  13. Zuo L, Prather ER, Stetskiv M, et al. Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. Int J Mol Sci. 2019;20(18):4472. doi: 10.3390/ijms20184472
  14. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30(10):2579–2582. doi: 10.2337/dc07-0320
  15. Xu B, Chibber R, Ruggiero D, et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003;17(10):1289–1291. doi: 10.1096/fj.02-0490fje
  16. Gryszczyńska B, Budzyń M, Begier-Krasińska B, et al. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension. Int J Mol Sci. 2019;20(16):3942. doi: 10.3390/ijms20163942
  17. Senatus LM, Schmidt AM. The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases. Front Genet. 2017;8:187. doi: 10.3389/fgene.2017.00187
  18. Kajikawa M, Nakashima A, Fujimura N, et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015;38(1):119–125. doi: 10.2337/dc14-1435
  19. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111(7):959–972. doi: 10.1172/JCI17115
  20. Liu Q, Chen HB, Luo M, Zheng H. Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. Genet Mol Res. 2016;15(2). doi: 10.4238/gmr.15028414
  21. Raposeiras-Roubin S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol. 2012;157(3):397–402. doi: 10.1016/j.ijcard.2011.05.072
  22. Prasad K, Manish M. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension? Int J Angiol. 2017;26(1):1–11. doi: 10.1055/s-0037-1598183
  23. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324–1330. doi: 10.1007/s00125-004-1451-2
  24. Kornilin DV, Grishanov VN, Cherepanov KV. Pulse excitation fluorescence meter for diagnostic purposes. Proc SPIE 10685, Biophotonics: Photonic Solutions for Better Health Care VI. 2018;1068515. doi: 10.1117/12.2306588
  25. Davydova NA, Lebedev PA, Ayupov AM, et al. Skin autofluorescence parameter as an adverse prognosis factor in patients with peripheral forms of atherosclerosis. Saratov Journal of Medical Scientific Research. 2022;18(4):568–575. (In Russ).
  26. Zhang Y, Jiang T, Liu C, et al. Effectiveness of Early Advanced Glycation End Product Accumulation Testing in the Diagnosis of Diabetes: AHealth Risk Factor Analysis Using the Body Mass Index as a Moderator. Front Endocrinol (Lausanne). 2022;12:766778. doi: 10.3389/fendo.2021.766778
  27. Saz-Lara A, Álvarez-Bueno C, Martínez-Vizcaíno V, et al. Are Advanced Glycation End Products in Skin Associated with Vascular Dysfunction Markers? A Meta-Analysis. Int J Environ Res Public Health. 2020;17(18):6936. doi: 10.3390/ijerph17186936
  28. van Eupen MG, Schram MT, van Sloten TT, et al. Skin autofluorescence and pentosidine are associated with aortic stiffening: the Maastricht study. Hypertension. 2016;68(4):956–963. doi: 10.1161/HYPERTENSIONAHA.116.07446
  29. Birukov A, Cuadrat R, Polemiti E, et al. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study. Cardiovasc Diabetol. 2021;20(1):110. doi: 10.1186/s12933-021-01296-5
  30. Jujić A, Östling G, Persson M, et al. Skin autofluorescence as a measure of advanced glycation end product levels is associated with carotid atherosclerotic plaque burden in an elderly population. Diab Vasc Dis Res. 2019;16(5):466–473. doi: 10.1177/1479164119845319
  31. Mitchell JD, Paisley R, Moon P, et al. Coronary artery calcium and long-term risk of death, myocardial infarction, and stroke: The Walter Reed Cohort Study. JACC Cardiovasc Imaging. 2018;11(12):1799–1806. doi: 10.1016/j.jcmg.2017.09.003
  32. Pan J, Bao X, Gonçalves I, et al. Skin autofluorescence, a measure of tissue accumulation of advanced glycation end products, is associated with subclinical atherosclerosis in coronary and carotid arteries. Atherosclerosis. 2022;345:26–32. doi: 10.1016/j.atherosclerosis
  33. Sanchez E, Betriu A, Yeramian A, et al. Skin autofluorescence measurement in subclinical atheromatous disease: results from the ILERVAS project. J Atheroscler Thromb. 2019;26(10):879–889. doi: 10.5551/jat.47498
  34. Fujino Y, Attizzani GF, Tahara S, et al. Association of skin autofluorescence with plaque vulnerability evaluated by optical coherence tomography in patients with cardiovascular disease. Atherosclerosis. 2018;274:47–53. doi: 10.1016/j.atherosclerosis.2018.03.001
  35. Hangai M, Takebe N, Honma H, et al., Association of advanced glycation end products with coronary artery calcification in Japanese subjects with type 2 diabetes as assessed by skin autofluorescence. J Atherosclerosis Thromb. 2016;23(10):1178–1187. doi: 10.5551/jat.30155
  36. Sánchez E, Betriu À, Arroyo D, et al. Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study. PLoS One. 2017;12(1):e0170778. doi: 10.1371/journal.pone.0170778
  37. Siriopol D, Hogas S, Veisa G, et al. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. Int Urol Nephrol. 2015;47(3):563–569. doi: 10.1007/s11255-014-0870-3
  38. van Waateringe RP, Fokkens BT, Slagter SN, et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia. 2019;62(2):269–280. doi: 10.1007/s00125-018-4769-x
  39. Jin Q, Lau ESH, Luk AOY, et al. Skin autofluorescence is associated with higher risk ofcardiovascular events in Chinese adults with type 2 diabetes: A prospective cohort study from the Hong Kong Diabetes Biobank. J Diabetes Complications. 2021;35(10):108015. doi: 10.1016/j.jdiacomp.2021.108015
  40. Boersma HE, van Waateringe RP, van der Klauw MM, et al. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. BMC Endocr Disord. 2021;21(1):14. doi: 10.1186/s12902-020-00676-4
  41. Shardlow A, McIntyre NJ, Kolhe NV, et al. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospectivecohort study. PLoS Med. 2020;17(7):e1003163. doi: 10.1371/journal.pmed.1003163
  42. Fraser SD, Roderick PJ, McIntyre NJ, et al. Skin autofluorescence and all-cause mortality in stage 3 CKD. Clin J Am Soc Nephrol. 2014;9(8):1361–1368. doi: 10.2215/CJN.09510913
  43. Cavero-Redondo I, Soriano-Cano A, Alvarez-Bueno C, et al. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. J Am Heart Assoc. 2018;7(18):e009833. doi: 10.1161/JAHA.118. 009833
  44. deVos LC, Noordzij MJ, Mulder DJ, et al. Skin autofluorescence as a measure of advanced glycation end product deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol. 2013;33(1):131–138. doi: 10.1161/ATVBAHA.112.300016
  45. de Vos LC, Mulder DJ, Smit AJ, et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol. 2014;34(4):933–938. doi: 10.1161/ATVBAHA.113.302731
  46. Kunimoto M, Yokoyama M, Shimada K, et al. Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation. Cardiovasc Diabetol. 2021;20(1):208. doi: 10.1186/s12933-021-01398-0

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies